The performance of public funds has witnessed remarkable divergence since the start of this year, with a striking gap of nearly 150 percentage points separating the top-performing active equity funds from the worst. Notably, the leading funds have recorded returns nearing 130%, whereas some funds have plummeted by over 18%. The standout funds owe their success to astute investments in innovative drugs, technology, new consumption trends, and other burgeoning sectors. Concurrently, these high-performing funds are encountering purchase restrictions, while newly launched funds are garnering significant market attention and substantial capital inflows.